The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing
Open Access
- 1 August 1991
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 1 (5) , 205-208
- https://doi.org/10.1111/j.1525-1438.1991.tb00041.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A Phase II Trial of Mitomycin in Patients with Epithelial Ovarian Carcinoma Resistant to Cisplatin or CarboplatinAmerican Journal of Clinical Oncology, 1990
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990
- Cisplatin/carboplatin cross-resistance in ovarian cancerBritish Journal of Cancer, 1989
- Modification of tumor cells by a low dose of Newcastle disease virusCancer Immunology, Immunotherapy, 1989
- RANDOMISED COMPARISON OF CISPLATIN WITH CYCLOPHOSPHAMIDE/CISPLATIN AND WITH CYCLOPHOSPHAMIDE/DOXORUBICIN/ CISPLATIN IN ADVANCED OVARIAN CANCERThe Lancet, 1987
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdensCancer, 1983